Fig 2: MARVEL domain-containing 1 (MARVELD1) is associated with biological processes in colon cancer. (A-B) Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of MARVELD1 in colon cancer. (C-R) MARVELD1 expression correlates with BICC1, CDH2, CTHRC1, DKK3, GLI1, GLI3, GREM1, HECW1, IGFBP4, IGFBP6, LATS2, MCC, PRICKLE1, SNAI2, SOX17, WWTR1 from the Wnt signaling pathway. All statistical tests were two-tailed, and P < 0.05 indicated statistical significance.

Fig 3: MARVEL domain-containing 1 (MARVELD1) promoter locus hypermethylation is inversely correlated with MARVELD1 expression in human cancer. (A) MARVELD1 promoter locus hypermethylation is inversely correlated with MARVELD1 expression in a pan-cancer cohort. (B-N) MARVELD1 promoter locus hypermethylation is inversely and significantly correlated with MARVELD1 expression in BLCA, CHOL, COAD, HNSC, KIRC, KIRP, PAAD, PCPG, SARC, SKCM, THCA, THYM, and UCEC from The Cancer Genome Atlas (TCGA) database. All statistical tests were two-tailed, and P < 0.05 indicated statistical significance.

Fig 4: Rescue experiments of MARVELD1. (A) HCT116 and HT29 cells with MARVELD1 overexpression or control transfection were first incubated with or without 20 mmol/L LiCl and then the inhibition of ß-catenin expression was partly reversed by western blotting in the nucleus and in the total protein. (B-E) HCT116 and HT29 cells with MARVELD1 overexpression or control transfection were first incubated with or without 20 mmol/L LiCl and then the inhibition of proliferation was partly reversed by the CCK-8 and clonogenic assays. (F-I) HCT116 and HT29 cells with MARVELD1 overexpression or control transfection were first incubated with or without 20 mmol/L LiCl and then the inhibition of migration and invasion were partly reversed by the wound healing and transwell assays. *p< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, no significance.

Fig 5: Expression of MARVEL domain-containing 1 (MARVELD1) in tumor and non-tumor tissues, the relationship between its expression and cancer prognosis in human cancers. (A) MARVELD1 expression is lower in the cancer cohort than in the corresponding normal tissues as observed in the data from The Cancer Genome Atlas (TCGA). (B) MARVELD1 expression is lower in UCEC, PRAD, LUAD, LIHC, KICH, COAD, CESC, BRCA, and BLCA than in the corresponding normal tissues. (C,D) Low expression of MARVELD1 correlates with poor disease specific survival (DSS) and progression free interval (PFI) according to TCGA pan-cancer database. (E,F) Low expression of MARVELD1 in COAD correlates with poor overall survival (OS) and progression free survival (PFS) in our cohort. (G,H) Low expression of MARVELD1 in PAAD correlates with poor OS in our cohort. *p< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, no significance.